Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA)
CUSIP: 29384C108
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Shares outstanding
- 38,346,880
- Total 13F shares
- 29,583,750
- Share change
- -652,891
- Total reported value
- $198,790,015
- Put/Call ratio
- 0%
- Price per share
- $6.72
- Number of holders
- 105
- Value change
- -$4,881,409
- Number of buys
- 66
- Number of sells
- 48
Quarterly Holders Quick Answers
What is CUSIP 29384C108?
CUSIP 29384C108 identifies TRDA - Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 29384C108:
Top shareholders of TRDA - Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| MPM BioVentures 2014, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,381,062
|
$88,628,884 | — | 10 Dec 2024 | |
| MPM BIOVENTURES 2018, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,381,062
|
$88,628,884 | — | 10 Dec 2024 | |
| ROCHE HOLDING LTD |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
2,813,525
|
$44,988,265 | — | 02 Nov 2021 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
13%
|
4,865,819
|
$43,987,004 | — | 31 Mar 2025 | |
| 5AM Venture Management, LLC |
13F
|
Company |
11%
|
4,408,379
|
$39,851,746 | — | 31 Mar 2025 | |
| MPM ASSET MANAGEMENT LLC |
13F
|
Company |
11%
|
4,381,062
|
$39,604,800 | — | 31 Mar 2025 | |
| Redmile Group, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,954,420
|
$31,251,176 | — | 02 Nov 2021 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
7.1%
|
2,736,767
|
$24,742,000 | — | 31 Mar 2025 | |
| ROCHE FINANCE LTD |
13D/G
|
— |
6.9%
|
2,569,115
|
$23,019,270 | $0 | 31 Dec 2024 | |
| JANUS HENDERSON GROUP PLC |
13F
13D/G
|
Company |
4%
from 13D/G
|
2,121,654
|
$20,304,229 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
13D/G
|
Company |
5.3%
from 13D/G
|
1,990,853
|
$17,997,312 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
4.1%
|
1,575,594
|
$14,243,370 | — | 31 Mar 2025 | |
| FMR LLC |
13F
|
Company |
3.2%
|
1,239,811
|
$11,207,892 | — | 31 Mar 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
2.7%
|
1,053,314
|
$9,521,958 | — | 31 Mar 2025 | |
| StepStone Group LP |
13F
|
Company |
2%
|
761,277
|
$6,881,944 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.5%
|
589,075
|
$5,326,635 | — | 31 Mar 2025 | |
| TCG Crossover Management, LLC |
13F
|
Company |
1.5%
|
584,955
|
$5,287,993 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
1.3%
|
494,388
|
$4,469,268 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.86%
|
328,485
|
$2,969,504 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.85%
|
327,127
|
$2,959,036 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.81%
|
310,187
|
$2,804,091 | — | 31 Mar 2025 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.55%
|
210,873
|
$1,906,292 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.5%
|
192,717
|
$1,742,162 | — | 31 Mar 2025 | |
| Peter S. Kim |
3/4/5
|
Director |
—
mixed-class rows
|
136,412
mixed-class rows
|
$1,712,677 | — | 11 Jun 2025 | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP |
13F
|
Company |
0.32%
|
123,898
|
$1,120,038 | — | 31 Mar 2025 | |
| MOORE CAPITAL MANAGEMENT, LP |
13F
|
Company |
0.27%
|
105,000
|
$949,200 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.26%
|
100,060
|
$904,542 | — | 31 Mar 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.26%
|
98,720
|
$892,428 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.24%
|
92,540
|
$836,564 | — | 31 Mar 2025 | |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ |
13F
|
Company |
0.23%
|
86,310
|
$780,242 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.19%
|
73,661
|
$665,895 | — | 31 Mar 2025 | |
| FIRST TRUST ADVISORS LP |
13F
|
Company |
0.19%
|
72,489
|
$655,300 | — | 31 Mar 2025 | |
| Nerissa Kreher |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
61,537
mixed-class rows
|
$640,192 | — | 01 Sep 2023 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.18%
|
67,793
|
$612,849 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.17%
|
67,016
|
$605,824 | — | 31 Mar 2025 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.15%
|
56,472
|
$510,507 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.13%
|
51,039
|
$461,393 | — | 31 Mar 2025 | |
| Nan Fung Group Holdings Ltd |
13F
|
Company |
0.13%
|
49,082
|
$443,701 | — | 31 Mar 2025 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.12%
|
47,788
|
$432,004 | — | 31 Mar 2025 | |
| STRS OHIO |
13F
|
Company |
0.11%
|
41,800
|
$377,872 | — | 31 Mar 2025 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.11%
|
41,023
|
$370,848 | — | 31 Mar 2025 | |
| MARTINGALE ASSET MANAGEMENT L P |
13F
|
Company |
0.1%
|
40,163
|
$363,075 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.1%
|
39,651
|
$358,445 | — | 31 Mar 2025 | |
| LAZARD ASSET MANAGEMENT LLC |
13F
|
Company |
0.1%
|
39,711
|
$358,000 | — | 31 Mar 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.09%
|
36,113
|
$326,452 | — | 31 Mar 2025 | |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC |
13F
|
Company |
0.09%
|
33,593
|
$303,681 | — | 31 Mar 2025 | |
| Swiss National Bank |
13F
|
Company |
0.09%
|
32,800
|
$296,512 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.08%
|
31,960
|
$288,918 | — | 31 Mar 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.08%
|
30,919
|
$279,507 | — | 31 Mar 2025 | |
| WCG Wealth Advisors LLC |
13F
|
Company |
0.08%
|
28,830
|
$260,623 | — | 31 Mar 2025 |
Institutional Holders of Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) as of Q2 2025
As of 30 Jun 2025,
Entrada Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TRDA) was held by
105 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
29,583,750 shares.
The largest 10 holders included
BAKER BROS. ADVISORS LP, MPM ASSET MANAGEMENT LLC, 5AM Venture Management, LLC, PRICE T ROWE ASSOCIATES INC /MD/, BlackRock, Inc., VANGUARD GROUP INC, JANUS HENDERSON GROUP PLC, WELLINGTON MANAGEMENT GROUP LLP, StepStone Group LP, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
105
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
110
Q2 2025 holders
105
Holder diff
-5
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.